-- ルモス・ダイアグノスティクス・ホールディングス（ASX:LDX）は、同社の迅速ポイントオブケア検査キット「FebriDx」が米国食品医薬品局（FDA）の臨床検査改善修正法（CLIA）免除を取得したことにより、生物医学先端研究開発局（BARDA）との契約に基づき、50万7,377ドルのマイルストーン支払いを受け取った。これは、木曜日にオーストラリア証券取引所に提出された書類で明らかになった。 BARDAからのこの支払いにより、CLIA免除研究で受け取った総額は300万ドル近くになった。
Related Articles
Asia
Toho Zinc Issues Shares Following Partial Warrant Exercise by Apricus Partners
Toho Zinc (TYO:5707) said 5,936 units of its first series share acquisition rights were exercised in April, resulting in the delivery of 593,600 shares, according to a Thursday filing on the Tokyo Stock Exchange.The exercised warrants represented 17% of the total 35,000 units issued through a third-party allotment to Apricus Partners in April.Outstanding share acquisition rights declined to 27,184 units, equivalent to 2.7 million shares, at the end of April from 33,120 units a month earlier.
$TYO:5707
Asia
Linyang Energy Recommended As Winner for State Grid's Bids
The State Grid Corporation of China recommended Jiangsu Linyang Energy (SHA:601222) as a winning candidate for its meter procurement bids, according to a Shanghai bourse filing on Thursday.The total winning amount is expected to be approximately 220.1 million yuan.The Chinese energy services provider's shares rose by less than 2% at the close.
$SHA:601222
Asia
Tokyo Kiraboshi to Discuss Capital Policy at Board Meeting
Tokyo Kiraboshi Financial (TYO:7173) said media reports regarding the redemption of preferred shares held by the Tokyo Metropolitan Government were not based on information disclosed by the company, according to a Wednesday filing on the Tokyo Stock Exchange.The lender said it is considering various capital policy options, including redeeming preferred shares, as part of its management strategy, though no decision has been made.Tokyo Kiraboshi said its board plans to discuss the matter on May 8.
$TYO:7173